Literature DB >> 24993621

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non-small cell lung cancer.

Shuenn-Wen Kuo1, Jin-Shing Chen1, Pei-Ming Huang1, Hsao-Hsun Hsu1, Hong-Shiee Lai1, Jang-Ming Lee2.   

Abstract

OBJECTIVE: For stage I non-small cell lung cancer (NSCLC), the only 2 prognostic factors incorporated into the seventh edition of the TNM staging system were tumor size and visceral pleural invasion. However, with this staging system, the prognostic precision of survival has proved elusive, suggesting the need to include additional prognostic factors. To improve prognostic applications and treatment decisions, we investigated clinicopathologic factors affecting progression-free survival in patients with surgically resected stage I NSCLC.
METHODS: From January 2004 to December 2011, we retrospectively reviewed the clinicopathologic characteristics of 758 consecutive patients with surgically resected stage I NSCLC at the National Taiwan University Hospital.
RESULTS: The 5-year progression-free survival rate was 82.3% and 64.0% for those with stage IA (n=481) and stage IB (n=277), respectively. Multivariate analysis revealed poor or moderate histologic differentiation and elevated preoperative serum carcinoembryonic antigen were statistically significant risk factors for recurrence in patients with stage IA. Poor or moderate histologic differentiation, elevated preoperative serum carcinoembryonic antigen, lymphovascular invasion, and tumor size>2 cm were statistically significant risk factors for recurrence in patients with stage I NSCLC. The 5-year progression-free survival rate was 93.0%, 73.8%, and 40.6% for stage I patients with no, 1 or 2, and >2 risk factors, respectively (P<.001).
CONCLUSIONS: In addition to tumor size, we identified 3 other independent risk factors for recurrence in patients with stage I NSCLC. These 3 risk factors warrant consideration as additional predictors in the next version of the TNM staging system.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24993621     DOI: 10.1016/j.jtcvs.2014.04.038

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  13 in total

1.  Prognosis After Sublobar Resection of Small-sized Non-small Cell Lung Cancer with Visceral Pleural or Lymphovascular Invasion.

Authors:  Youngkyu Moon; Kyo Young Lee; Jae Kil Park
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

2.  Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer.

Authors:  Lucas W Thornblade; Michael S Mulligan; Katherine Odem-Davis; Billanna Hwang; Rachel L Waworuntu; Erika M Wolff; Larry Kessler; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2018-07-19       Impact factor: 4.330

3.  The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures.

Authors:  Qihua He; Peiling Xin; Mingzhe Zhang; Si Jiang; Jianrong Zhang; Shengyi Zhong; Yang Liu; Minzhang Guo; Xuewei Chen; Xiaojun Xia; Zhenkui Pan; Chenye Guo; Xiuyu Cai; Wenhua Liang; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2019-04

4.  A retrospective comparative analysis of elderly and younger patients undergoing pulmonary resection for stage I non-small cell lung cancer.

Authors:  Byungjoon Park; Genehee Lee; Hong Kwan Kim; Yong Soo Choi; Jae Il Zo; Young Mog Shim; Jhingook Kim
Journal:  World J Surg Oncol       Date:  2016-01-19       Impact factor: 2.754

Review 5.  Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer.

Authors:  Ying-Yi Chen; Tsai-Wang Huang; Hung Chang; Shih-Chun Lee
Journal:  Lung Cancer (Auckl)       Date:  2016-03-30

Review 6.  [Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer].

Authors:  Bo Liu; Fengxia Ding; Shuangqiang Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-06

7.  Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery.

Authors:  Lu Yang; Chong Pang; Fei Xu; Guangjian Yang; Haiyan Xu; Changli Wang; Yan Wang
Journal:  Cancer Manag Res       Date:  2020-12-07       Impact factor: 3.989

8.  Is the size of the lepidic component negligible when measuring the size of the tumor to determine the stage of lung adenocarcinoma?

Authors:  Youngkyu Moon
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

9.  Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule.

Authors:  Jong Hui Suh; Jae Kil Park; Youngkyu Moon
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

10.  Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer.

Authors:  Xiaofei Yu; Zhengwei Dong; Wanying Wang; Shiqi Mao; Yingying Pan; Yiwei Liu; Shuo Yang; Bin Chen; Chunyan Wang; Xuefei Li; Chao Zhao; Keyi Jia; Chuchu Shao; Chunyan Wu; Shengxiang Ren; Caicun Zhou
Journal:  Cancer Manag Res       Date:  2021-05-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.